SCHEMBL719499

SCHEMBL719499

COC(=O)c1ccc(NC(COc2ccccc2)c2oc3ccccc3c2C)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.45
RAB9A P51151 2/20 0.45
KDM4E B2RXH2 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.41
TNKS O95271 1/20 0.41
ADRB2 P07550 1/20 0.41
ADRB1 P08588 1/20 0.41
ADRB3 P13945 1/20 0.41
NPC1 O15118 1/20 0.40
LMNA P02545 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA12 O43570 1/20 0.40
CA9 Q16790 1/20 0.40
TP53 P04637 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL720711 0.92 CA12 (0.49) MAPTKDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL718863 0.84 TNKS (0.43) MAPTRAB9AKDM4ESMN1; SMN2MEN1
SCHEMBL721127 0.84 RAB9A (0.39) MAPTRAB9AKDM4ESMN1; SMN2L3MBTL1
SCHEMBL2669949 0.84 ADRB2 (0.44) MAPTRAB9AKDM4ESMN1; SMN2MEN1
SCHEMBL718011 0.82 MAPT (0.42) MAPTRAB9AKDM4ESMN1; SMN2L3MBTL1
SCHEMBL719600 0.81 MAPT (0.38) MAPTRAB9AL3MBTL1NPC1LMNA
SCHEMBL3407767 0.73 LMNA (0.45) MAPTRAB9AKDM4ESMN1; SMN2KMT2A
SCHEMBL719177 0.73 KMT2A (0.47) MAPTRAB9AKDM4ESMN1; SMN2MEN1
SCHEMBL721304 0.70 MAPT (0.45) MAPTRAB9AKDM4ESMN1; SMN2MEN1
SCHEMBL719406 0.70 KDM4E (0.45) MAPTRAB9AKDM4ESMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP MAPT 4533/4885RAB9A 2454/4885KDM4E 1907/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP MAPT 4533/4885RAB9A 2454/4885KDM4E 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.